MGMT status is a well-known predictor of chemosensitivity in glioblastoma [47]; thus, in order to understand its role in astrocytoma, we investigated the MSKCC chemotherapy-treated cohort and the CGGA recurrent chemotherapy-treated cohort where the MGMT statuses were known and performed survival analysis based on TP53 mutation and YAP1 mRNA expression levels, respectively. The gene discussed is YAP1; the disease is astrocytoma (excluding glioblastoma).